Bortezomib remains a cornerstone treatment for multiple myeloma and mantle cell lymphoma, and Chicago's Northwestern Memorial and University of Chicago Medicine manage significant patient volumes requiring this proteasome inhibitor. Bortenat 3.5mg provides identical treatment at significantly reduced institutional cost.
Bortenat is given subcutaneously or intravenously, with subcutaneous administration now preferred in most Chicago oncology centres due to lower peripheral neuropathy rates while maintaining equivalent efficacy. Standard dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone and Lenalidomide or Cyclophosphamide.
Chicago hospital pharmacies seeking cost-effective Bortezomib procurement can access Bortenat with full WHO-GMP documentation for formulary approval.
Bortenat is given subcutaneously or intravenously, with subcutaneous administration now preferred in most Chicago oncology centres due to lower peripheral neuropathy rates while maintaining equivalent efficacy. Standard dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone and Lenalidomide or Cyclophosphamide.
Chicago hospital pharmacies seeking cost-effective Bortezomib procurement can access Bortenat with full WHO-GMP documentation for formulary approval.
What is peripheral neuropathy and why does Bortenat cause it?Peripheral neuropathy refers to nerve damage typically affecting the hands and feet, causing tingling, numbness, burning sensations, or pain. Bortezomib can cause this side effect because the drug's mechanism — inhibiting the proteasome, a structure that breaks down damaged proteins in cells — can also disrupt normal nerve cell function over time. The risk is meaningfully lower with subcutaneous administration compared to IV, which is why this route is now generally preferred. Symptoms often improve after treatment ends, though recovery can take months.